Novo Nordisk A/S understated the impact of lookalike weight-loss injections on its market share before lowering its 2025 ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

When it was riding high, Novo Nordisk could have done M&A to reduce its dependence on obesity treatments. It didn’t.

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, ...

Ozempic maker Novo Nordisk surges past Tesla with market value of $566B By Reuters Published March 7, 2024, 11:52 a.m. ET ...

The soaring popularity of weight loss drugs Ozempic and Wegovy has catapulted parent company Novo Nordisk’s valuation past the half-trillion dollar threshold, according to a report. The Danish ...

Novo Nordisk’s Wegovy is FDA-approved for weight loss, while its lower-dose GLP-1 cousin Ozempic is only officially approved for Type 2 diabetes but is often prescribed off-label for weight loss.

In 2023, sales from Novo Nordisk's GLP-1 diabetes therapies grew 52% year over year. Ozempic and a sibling treatment called Rybelsus are to thank for that growth.

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.